Indication and safety information:

Menactra^® is a vaccine that is used to prevent meningococcal diseases and/or septicemia (blood poisoning) caused by bacteria called Neisseria meningitidis (serogroups A, C, Y and W-135). This vaccine may be given to persons 9 months through 55 years of age. Menactra^® is not indicated for the prevention of invasive meningococcal disease caused by serogroup B. Menactra^® is not to be used for the treatment of invasive meningococcal disease, and cannot prevent complications or death after the onset of the disease. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS after receiving Menactra^®. Persons with an allergy to any component of the vaccine or the container should not receive the vaccine. As with any vaccine, Menactra^® may not protect 100% of vaccinated individuals. Adverse reactions and side effects may occur. The most common side effects in adolescents and adults (11-55 years old) were pain, induration, redness and swelling at the injection site, and headache, fatigue and malaise. Talk to your healthcare provider to see if Menactra^® is right for you or a family member. For more information, visit www.sanofi.ca.

Fluzone^® Quadrivalent is a vaccine used to prevent influenza caused by the 4 strains of influenza virus (A/H1N1, A/H3N2, B/Victoria lineage, B/Yamagata lineage) contained in the vaccine. This vaccine may be given to adults and children 6 months of age and older. Persons with a history of severe allergic reaction to eggs or egg products or any component of Fluzone^® Quadrivalent should not receive the vaccine. Fluzone^® Quadrivalent will only protect against the strains of influenza virus contained in the vaccine or those that are closely related. It will not protect against any other strains of influenza virus. As with any vaccine, immunization with influenza vaccine may not protect 100% of individuals. Because flu viruses change over time, annual influenza vaccination is recommended for influenza. Some persons may experience side effects and allergic reactions. The most common are soreness at the site of injection and muscle pain, and infants may suffer from irritability. Most patients recover. Talk to your healthcare provider to ensure that Fluzone^® Quadrivalent is right for you. For more information, visit www.sanofi.ca.

Fluzone^® High-Dose Quadrivalent is a vaccine used to prevent influenza in adults 65 years of age and older. Influenza (or flu) is an infection caused by the influenza virus. Annual vaccination using the current vaccine is recommended for prevention against influenza as immunity declines in the year following vaccination and because circulating strains of influenza virus change from year to year. Persons with a history of severe allergic reaction to eggs or egg products or any component of Fluzone^® High-Dose Quadrivalent should not receive the vaccine. Fluzone^® High-Dose Quadrivalent will only protect against the strains of influenza virus contained in the vaccine or those that are closely related. Fluzone^® High-Dose Quadrivalent will not protect against any other strains of influenza virus. Fluzone^® High-Dose Quadrivalent is not indicated for the prevention of hospitalization or death or to reduce the risk of complications after the onset of disease. As with all vaccines, Fluzone^® High-Dose Quadrivalent does not protect 100% of people immunized. The most common side effects are pain at the injection site, muscle ache. Allergic reactions can occur. Contact your healthcare provider to see if this vaccine is right for you. For more information, visit www.sanofi.ca.

Supemtek^TM is a vaccine used to prevent influenza. This vaccine may be given to adults 18 years and older. Annual influenza vaccination is recommended because immunity during the year after vaccination declines and because circulating strains of influenza virus change from year to year. People who have a known severe allergy to any ingredient in Supemtek^TM or who have had a severe allergic reaction after receiving a vaccine that contained similar ingredients should not use Supemtek^TM. Supemtek^TM will only protect against the strains of influenza virus contained in the vaccine or those that are closely related. Supemtek^TM will not protect against any other strains of influenza virus. Supemtek^TM is not indicated for the prevention of hospitalization or death or to reduce the risk of complications after the onset of disease. As with all vaccines, Supemtek^TM does not protect 100% of people immunized. The most common side effects are local pain and tenderness, fatigue, headache and muscle and joint pain. Talk to your doctor, nurse or pharmacist to see if this vaccine is right for you. For more information, visit www.sanofi.ca.

TYPHIM Vi^® is a vaccine used to prevent typhoid fever. This vaccine may be given to persons 2 years of age and older caused by bacteria called Salmonella typhi. TYPHIM Vi^® causes the body to produce its own natural protection against typhoid fever. After you receive the vaccine, your body begins to make substances called antibodies. Antibodies help the body to fight disease. If a vaccinated person comes into contact with the germ that causes this disease, the body is usually ready to destroy it. The majority of persons who are vaccinated with TYPHIM Vi^® will produce enough antibodies to provide protection against typhoid fever by 2 weeks after the first vaccination. Individuals travelling to typhoid fever risk areas should receive the vaccine at least 2 weeks prior to departure in order to have an adequate protective response. However, as with all vaccines, 100% protection cannot be guaranteed. The body does not develop long-term protection against typhoid fever. Hence repeat vaccination 2-3 years after previous vaccination is recommended for individuals at continued risk of exposure to typhoid fever causing bacteria. Serious side effects are rare. Some people who receive TYPHIM Vi^® may have mild side effects such as pain or tenderness at the injection site, associated with redness and swelling. Other possible side effects commonly reported may include fever, headache, general feeling of weakness and discomfort, and muscle pain. These side effects usually go away within a few days. Talk to your healthcare provider to see if TYPHIM Vi^® is right for you or a family member. For more information, visit www.sanofi.ca.

AVAXIM^® is a vaccine that is used to prevent hepatitis A infection. This vaccine may be given to persons 12 years of age or older. Hepatitis A is a contagious liver disease that is spread from person to person through drinking water or eating food with the hepatitis A virus (HAV) in it. It is also spread by close personal contact. It is more common in areas of the world with poor sanitation. Hepatitis A can cause a mild illness, but about 1 person in 5 has to be hospitalized and sometimes people die as a result of hepatitis A. The majority of persons who are vaccinated with AVAXIM^® will produce enough antibodies to help protect them against this disease. However, as with all vaccines, 100% protection cannot be guaranteed.

AVAXIM^® causes the body to produce its own natural protection against hepatitis A infection. After you receive the vaccine, your body begins to make substances called antibodies. Antibodies help the body to fight disease. If a vaccinated person comes into contact with the germ that causes this disease, the body is usually ready to destroy it.

These are not all the possible side effects you may feel when taking AVAXIM^®. If you experience any side effects not listed here, contact your healthcare professional. A vaccine, like any medicine, may cause serious problems. Serious or even life-threatening allergic reactions (anaphylactic reactions, including shock) can always happen, even if they are very rare. If you experience an allergic reaction, contact your doctor or healthcare professional immediately or go to the nearest hospital emergency room right away. The risk of AVAXIM^® causing serious harm is extremely small. The risks associated with AVAXIM^® are much less than the risks associated with getting the diseases. These side effects usually go away within a few days. Serious side effects are very rare. Talk to your healthcare provider to see if AVAXIM^® is right for you or a family member. For more information, visit www.sanofi.ca.

IMOVAX^® Rabies is a vaccine used to prevent rabies. IMOVAX^® Rabies is given to persons at high risk of exposure to rabies as a result of their employment, travel, hobbies, etc. It can also prevent the disease if it is given to a person after they have been exposed to rabies following an animal bite or other similar incident. This vaccine may be given to adults and children of any age. IMOVAX^® Rabies causes your body to produce its own protection against the rabies virus. When you get a series of rabies vaccine injections, your immune system produces antibodies against the virus in the vaccine. When you are in contact with the rabies virus, the antibodies will prevent rabies disease. A series of shots is needed to protect you or your child against rabies. As with any vaccine, immunization with IMOVAX^® Rabies may not protect 100% of individuals.

Tell your doctor, nurse or pharmacist as soon as possible if you do not feel well after receiving. IMOVAX^® Rabies. Rabies vaccine cannot cause rabies because it does not contain any live virus. Some people who receive IMOVAX^® Rabies may have side effects such as swollen lymph nodes, hives, rash, shortness of breath, wheezing, headache, dizziness, nausea, abdominal pain, vomiting, diarrhea, muscle aches, pain in joints, bodily discomfort, fever or chills. Some people who receive IMOVAX^® Rabies may have pain, redness, swelling, bruising or itching at the site where the needle was given. Nervous system disorders have been reported after rabies vaccine, but this happens so rarely that it is not known if they are related to the vaccine.

These are not all the possible side effects you may have when taking IMOVAX^® Rabies. A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. The risk of IMOVAX^® Rabies causing serious harm is extremely small. The small risks associated with IMOVAX^® Rabies are much less than the risks associated with getting rabies.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional. Talk to your healthcare provider to see if IMOVAX^® Rabies is right for you or a family member. For more information, visit www.sanofi.ca.

YF-VAX^® is a vaccine that is used to help prevent yellow fever. This vaccine may be given to adults and children 9 months of age and older who are:

• travelling to or living in countries and areas where yellow fever infection is officially reported or considered to exist.
• travelling to countries where yellow fever vaccination is required by law upon entry. Current information on the countries for which an International Certificate of Vaccination or Prophylaxis is required can be obtained from local public health departments or from the Public Health Agency of Canada’s (PHAC) Travel Medicine Program web site.
• laboratory personnel who might be exposed to yellow fever virus or to concentrated preparations of the 17D vaccine strain.

The majority of persons who are vaccinated with YF-VAX^® will produce enough antibodies to protect them from this disease. However, as with all vaccines, 100% protection cannot be guaranteed.

YF-VAX^® causes your body to produce its own natural protection against the yellow fever virus. After you receive the vaccine, your body begins to make substances called antibodies. Antibodies help your body to fight disease. If a vaccinated person comes into contact with the yellow fever virus, the body is usually ready to destroy it.

These are not all the possible side effects you or your child may feel when taking YF-VAX^®. If you or your child experience any side effects not listed here, contact your healthcare professional. Please also see Warnings and Precautions. A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. The risk of YF-VAX^® causing serious harm is extremely small. The small risks associated with YF-VAX^® are much less than the risks of getting the disease against which it protects.

Tell your doctor or nurse as soon as possible if you do not feel well after receiving YF-VAX^®. Some people who receive YF-VAX^® may have mild side effects such as soreness, redness or swelling at the site of the injection. The side effects usually go away within a few days. Serious side effects are very rare.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional. Talk to your healthcare provider to see if YF-VAX^® is right for you or a family member. For more information, visit www.sanofi.ca.

Beyfortus^® (nirsevimab injection) is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:

• Neonates and infants during their first RSV season.
• Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, which may include but is not limited to children with: chronic lung disease of prematurity (CLD), hemodynamically significant congenital heart disease (CHD), immunocompromised states, down syndrome, cystic fibrosis, neuromuscular disease, and congenital airway anomalies.

Clinical use
Safety and efficacy in children older than 24 months of age have not been established. Safety and efficacy in infants with body weight below 1.6 kg have not been established. Dosing in infants with a body weight from 1.0 kg to <1.6 kg is based on extrapolation. The efficacy in infants who remain vulnerable to severe RSV disease during their first or second RSV season has not been directly established and is based on extrapolation of exposure only.

There is limited information available in extremely preterm infants (Gestational Age [GA] <29 weeks) less than 8 weeks of age, and no clinical data are available in infants with a postmenstrual age (gestational age at birth plus chronological age) of 32 weeks. Limited data are available in infants with Down syndrome (n=13), Cystic fibrosis (n=5), Congenital airway anomalies (n=9), and Neuromuscular disease (n=0; not evaluated in clinical trials).

Not indicated in the geriatric population (≥65 years of age).

Relevant warnings and precautions

• Should be given with caution to individuals with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.
• Serious hypersensitivity reactions, including anaphylaxis, have been observed rarely with other IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medicinal products and/or supportive therapy.
• Pregnant and nursing women: not indicated for adults.

For more information
Please refer to the Product Monograph for important information relating to adverse events, drug interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-265-7927.